For information related to Dermacyte insurance benefit verifications, assistance or claims appeal assistance, please contact our **Reimbursement Support Line.**

Phone: (919) 921-8105 Ext 119 Fax: (919) 267-3753 Email: info@merakris.com

Harnessing the power of amnion for the treatment of chronic wounds





Merakris Therapeutics Inc 800 Park Offices Drive, Suite 3322 Research Triangle Park, NC 27709 919.921.8105 www.merakris.com FDA Establishment Identifier (FEI): 3013695841

Dermacyte® is regulated by the U.S. FDA under 21 CFR Part 1271 and Section 361 of the Public Health Service Act. Dermacyte® is a registered trademark of Merakris Therapeutics Inc. Copyright © 2021 Merakris Therapeutics.

References:

1. Niknejad H et al. Properties of the amniotic membrane for potential use in tissue engineering. Eur Cell Mater. 2008 Apr 29;15:88-99. 2. Haugh A et al. Amnion membrane in diabetic foot wounds: a meta-analysis. Plastic and Reconstr Surg Glob Open. 2017 Apr; 5:e1302. 3. Guo et al. Modulation of cell attachment, proliferation, and angiogenesis by decellularized, dehydrated human amniotic membrane in in vitro models. Wounds. 2017 Jan;29(1):28-38.








A Powerful Regenerative Wound Matrix to Support Acute and Chronic Wound Closure

Dermacyte[®] products are derived from human postpartum amniotic tissues that have been processed to retain native extracellular matrix cytokines, growth factors, and collagen to support tissue remolding, improving patient outcomes and treatment comfort.



Easy to Use

Ready for Application

- Dehydrated for easy application with no refrigeration
- No preparation time required for thawing or soaking—
 reducing operative time

Easy to Handle

- Conforms to wound bed and naturally hydrates in place
- Superior handling and optimal bioabsorption properties

Improved Patient Experience

Use as protective wound barrier to provide an antimicrobial, growth factor rich healing environment

Promotes native tissue repair by minimizing fibrosis, reducing inflammation, and maximizing patient comfort

Simple Wound Monitoring

Routine dressing changes, wound cleansing, and Dermacyte® reapplication allows for easy assessment of wound closure.

Clinical Applications

Dermacyte® products are versatile coverings and void fillers that may be applied to various hard-to-heal wounds, including:

- Diabetic foot ulcers
- Venous stasis ulcers
- Burns
- Decubitus / Pressure Ulcers
- Surgical incisions
- Other dermal defects
 and wounds



Dermacyte®–A Unique Bioactive Wound Cove

Scaffolds:

The special structure and biological viability of amniotic membrane is ideal in tissue engineering. The extracellular matrix components of the basement membrane creates a natural scaffold for cell attachment.¹

Signals:

Amniotic tissue cytokines, grow and stem cells role in improve regeneration of immunogenici



Sufficient cues to allow for cell attachment and proliferation are properties of dehydrated amnion. Soluble factors secreted by human dermal fibroblasts cultured on amnion enhanced both endothelial cell and keratinocyte survival and endothelial cell migration in a wound closure assay.³

N		The	1
	ing 	Dermacyt	<image/>
e is rich in /th factors, that play a d healing and nd decreased :y. ²		SIZE 2 x 2 cm2 2 x 4 cm2 4 x 4 cm2 4 x 6 cm2	PRODUCT CODE AM-D10022 AM-D10024 AM-D10044 AM-D10046
	Actual sizes: 2cm x		AM-D10048 cm

Committed to Patient Safety

- All tissues are recovered and processed by a U.S. FDA registered and AATB accredited tissue bank
- A Licensed Medical Director confirms product eligibility through donor screening and testing records, and final culturing and sterility testing is confirmed prior to lot release